 Joseph Schacht
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 27 | 2025 | 807 | 5.830 |
Why?
| | Naltrexone | 7 | 2021 | 97 | 2.850 |
Why?
| | Cues | 18 | 2025 | 314 | 2.310 |
Why?
| | Catechol O-Methyltransferase | 4 | 2022 | 17 | 2.090 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 5 | 2021 | 57 | 1.940 |
Why?
| | Alcohol Drinking | 18 | 2025 | 828 | 1.730 |
Why?
| | Receptors, Opioid, mu | 5 | 2021 | 74 | 1.500 |
Why?
| | Marijuana Abuse | 8 | 2019 | 233 | 1.370 |
Why?
| | Narcotic Antagonists | 4 | 2021 | 181 | 1.320 |
Why?
| | Craving | 6 | 2025 | 39 | 1.270 |
Why?
| | Brain | 17 | 2025 | 2668 | 1.040 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2020 | 2189 | 1.030 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2019 | 179 | 0.990 |
Why?
| | gamma-Aminobutyric Acid | 4 | 2019 | 198 | 0.940 |
Why?
| | Pharmacogenomic Variants | 3 | 2017 | 35 | 0.770 |
Why?
| | Flumazenil | 2 | 2013 | 8 | 0.770 |
Why?
| | Cyclohexanecarboxylic Acids | 2 | 2013 | 22 | 0.760 |
Why?
| | Magnetic Resonance Imaging | 18 | 2024 | 3566 | 0.750 |
Why?
| | Amines | 2 | 2013 | 40 | 0.750 |
Why?
| | Reward | 5 | 2020 | 244 | 0.710 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 18 | 0.700 |
Why?
| | Aripiprazole | 2 | 2017 | 20 | 0.700 |
Why?
| | Dopamine Agonists | 2 | 2017 | 39 | 0.680 |
Why?
| | Functional Neuroimaging | 4 | 2024 | 55 | 0.610 |
Why?
| | Cocaine | 1 | 2021 | 166 | 0.600 |
Why?
| | Receptor, Cannabinoid, CB1 | 4 | 2012 | 45 | 0.600 |
Why?
| | Substance-Related Disorders | 3 | 2024 | 1083 | 0.590 |
Why?
| | Dopamine | 2 | 2022 | 303 | 0.560 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 660 | 0.550 |
Why?
| | Cognition | 3 | 2018 | 1153 | 0.510 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 660 | 0.510 |
Why?
| | Dopamine Agents | 1 | 2016 | 19 | 0.510 |
Why?
| | Brain Mapping | 4 | 2017 | 503 | 0.490 |
Why?
| | Prefrontal Cortex | 2 | 2016 | 301 | 0.480 |
Why?
| | Glutamic Acid | 5 | 2019 | 246 | 0.480 |
Why?
| | Ethanol | 6 | 2024 | 608 | 0.470 |
Why?
| | Nicotine | 1 | 2018 | 334 | 0.470 |
Why?
| | Amidohydrolases | 3 | 2009 | 31 | 0.450 |
Why?
| | Motivation | 6 | 2020 | 570 | 0.440 |
Why?
| | Benzazepines | 1 | 2014 | 39 | 0.430 |
Why?
| | Quinoxalines | 1 | 2014 | 66 | 0.420 |
Why?
| | Smoking | 2 | 2018 | 1627 | 0.400 |
Why?
| | Nicotinic Agonists | 1 | 2014 | 129 | 0.390 |
Why?
| | Adult | 29 | 2025 | 37929 | 0.390 |
Why?
| | Marijuana Smoking | 2 | 2019 | 252 | 0.350 |
Why?
| | Humans | 44 | 2025 | 137585 | 0.350 |
Why?
| | Cannabis | 1 | 2018 | 494 | 0.350 |
Why?
| | Gyrus Cinguli | 5 | 2025 | 86 | 0.350 |
Why?
| | Amygdala | 1 | 2012 | 191 | 0.350 |
Why?
| | Alcohol-Related Disorders | 1 | 2012 | 122 | 0.340 |
Why?
| | Male | 31 | 2025 | 67762 | 0.340 |
Why?
| | Genotype | 6 | 2020 | 1916 | 0.340 |
Why?
| | Young Adult | 17 | 2020 | 13209 | 0.330 |
Why?
| | Female | 31 | 2025 | 73304 | 0.330 |
Why?
| | Catechol O-Methyltransferase Inhibitors | 2 | 2022 | 3 | 0.320 |
Why?
| | Genetic Variation | 2 | 2012 | 991 | 0.320 |
Why?
| | Corpus Striatum | 1 | 2011 | 167 | 0.310 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2011 | 267 | 0.300 |
Why?
| | Glutamine | 2 | 2019 | 103 | 0.300 |
Why?
| | Treatment Outcome | 7 | 2021 | 10811 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2426 | 0.290 |
Why?
| | Hippocampus | 1 | 2012 | 895 | 0.260 |
Why?
| | Heterozygote | 2 | 2018 | 293 | 0.260 |
Why?
| | Middle Aged | 13 | 2025 | 33479 | 0.260 |
Why?
| | Receptors, Dopamine D2 | 2 | 2017 | 97 | 0.250 |
Why?
| | Acetaldehyde Dehydrogenase Inhibitors | 1 | 2025 | 1 | 0.230 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2025 | 23 | 0.230 |
Why?
| | Antipsychotic Agents | 2 | 2017 | 194 | 0.230 |
Why?
| | Benzamides | 1 | 2025 | 216 | 0.210 |
Why?
| | Neuroimaging | 2 | 2024 | 259 | 0.210 |
Why?
| | Benzodioxoles | 1 | 2025 | 115 | 0.210 |
Why?
| | Pharmacogenetics | 2 | 2016 | 180 | 0.210 |
Why?
| | Glutathione | 1 | 2025 | 356 | 0.200 |
Why?
| | Nerve Net | 2 | 2018 | 256 | 0.200 |
Why?
| | Behavior, Addictive | 3 | 2019 | 81 | 0.200 |
Why?
| | Cartilage Oligomeric Matrix Protein | 1 | 2021 | 3 | 0.180 |
Why?
| | Gene Frequency | 2 | 2016 | 521 | 0.180 |
Why?
| | Biomarkers | 3 | 2024 | 4149 | 0.170 |
Why?
| | Checklist | 1 | 2022 | 93 | 0.170 |
Why?
| | Ventral Striatum | 1 | 2020 | 8 | 0.170 |
Why?
| | Adolescent | 12 | 2024 | 21513 | 0.170 |
Why?
| | Double-Blind Method | 3 | 2025 | 1993 | 0.170 |
Why?
| | Appointments and Schedules | 1 | 2021 | 89 | 0.170 |
Why?
| | Anesthesia, General | 1 | 2021 | 77 | 0.170 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.160 |
Why?
| | Alcohol Abstinence | 1 | 2019 | 12 | 0.160 |
Why?
| | Aspartic Acid | 2 | 2019 | 79 | 0.160 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 179 | 0.160 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 1066 | 0.150 |
Why?
| | Homozygote | 2 | 2016 | 203 | 0.150 |
Why?
| | Binge Drinking | 1 | 2019 | 43 | 0.150 |
Why?
| | Therapy, Computer-Assisted | 1 | 2019 | 62 | 0.150 |
Why?
| | Avoidance Learning | 1 | 2019 | 76 | 0.150 |
Why?
| | Glycine | 1 | 2019 | 176 | 0.140 |
Why?
| | Frontal Lobe | 1 | 2019 | 149 | 0.140 |
Why?
| | Transferrin | 1 | 2018 | 47 | 0.140 |
Why?
| | Receptors, Dopamine D4 | 1 | 2017 | 26 | 0.140 |
Why?
| | Minisatellite Repeats | 1 | 2017 | 42 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5131 | 0.140 |
Why?
| | Sialoglycoproteins | 1 | 2018 | 159 | 0.140 |
Why?
| | Self Administration | 1 | 2017 | 123 | 0.140 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 3 | 2025 | 20 | 0.140 |
Why?
| | Central Nervous System Depressants | 1 | 2017 | 85 | 0.130 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2828 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2019 | 3556 | 0.130 |
Why?
| | Drug Interactions | 1 | 2018 | 410 | 0.130 |
Why?
| | Self-Control | 1 | 2017 | 54 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 282 | 0.130 |
Why?
| | Recurrence | 3 | 2020 | 1060 | 0.130 |
Why?
| | DNA Methylation | 1 | 2021 | 643 | 0.120 |
Why?
| | Receptors, Dopamine D1 | 1 | 2016 | 34 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2031 | 0.120 |
Why?
| | Hemodynamics | 1 | 2021 | 1113 | 0.120 |
Why?
| | Impulsive Behavior | 1 | 2017 | 150 | 0.120 |
Why?
| | Stress, Psychological | 1 | 2024 | 1100 | 0.120 |
Why?
| | Visual Perception | 1 | 2017 | 160 | 0.120 |
Why?
| | Receptors, GABA-A | 1 | 2016 | 142 | 0.110 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 5778 | 0.110 |
Why?
| | Attention | 1 | 2018 | 427 | 0.110 |
Why?
| | Cocaine-Related Disorders | 1 | 2015 | 113 | 0.110 |
Why?
| | Varenicline | 1 | 2014 | 25 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2019 | 530 | 0.110 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1023 | 0.110 |
Why?
| | GABA Modulators | 1 | 2013 | 12 | 0.100 |
Why?
| | Tobacco Use Disorder | 1 | 2015 | 251 | 0.100 |
Why?
| | Pilot Projects | 2 | 2019 | 1710 | 0.100 |
Why?
| | Tandem Repeat Sequences | 1 | 2012 | 21 | 0.100 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2013 | 100 | 0.100 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 696 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 429 | 0.090 |
Why?
| | Basal Ganglia | 1 | 2012 | 56 | 0.090 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 80 | 0.090 |
Why?
| | Secondary Prevention | 1 | 2013 | 233 | 0.090 |
Why?
| | Prognosis | 2 | 2017 | 4030 | 0.090 |
Why?
| | Functional Laterality | 1 | 2012 | 223 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 530 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 294 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 377 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 363 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.080 |
Why?
| | Prospective Studies | 2 | 2018 | 7604 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 849 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 515 | 0.070 |
Why?
| | Phenotype | 1 | 2016 | 3196 | 0.070 |
Why?
| | Protein Binding | 1 | 2012 | 2224 | 0.060 |
Why?
| | Alleles | 2 | 2020 | 891 | 0.060 |
Why?
| | Proof of Concept Study | 1 | 2025 | 78 | 0.060 |
Why?
| | Gene Expression | 1 | 2008 | 1502 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 816 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1477 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2022 | 3284 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2025 | 2057 | 0.040 |
Why?
| | Delphi Technique | 1 | 2022 | 280 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5472 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 1317 | 0.040 |
Why?
| | Photic Stimulation | 1 | 2019 | 241 | 0.040 |
Why?
| | Aged | 1 | 2018 | 23961 | 0.040 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 605 | 0.040 |
Why?
| | Animals | 2 | 2016 | 36940 | 0.030 |
Why?
| | Reaction Time | 1 | 2018 | 412 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 195 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2018 | 250 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 827 | 0.030 |
Why?
| | Oxygen | 2 | 2009 | 931 | 0.030 |
Why?
| | Valproic Acid | 1 | 2014 | 48 | 0.030 |
Why?
| | Taurine | 1 | 2014 | 46 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 611 | 0.030 |
Why?
| | Pregnancy | 1 | 2024 | 6763 | 0.020 |
Why?
| | Child | 2 | 2024 | 21935 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3295 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 399 | 0.020 |
Why?
| | Cannabinoids | 1 | 2009 | 161 | 0.020 |
Why?
| | Dronabinol | 1 | 2008 | 226 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 752 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 795 | 0.010 |
Why?
|
|
Schacht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|